Drug intelligence / Profile preview

onterodrimer

Development stage: Discontinued
Lead developer: Kaleido Biosciences
Modality: Small Molecules
Administration: Oral

Overview

**Onterodrimer** (formerly KB-195) is a targeted glycan **microbiome metabolic therapeutic (MMT)**, a type of **chemical drug** designed to modulate the gut microbiome for therapeutic benefit. Developed by **Kaleido Biosciences**, it targets **hyperammonemia**, a condition characterized by elevated ammonia levels often associated with urea cycle disorders. Its mechanism involves altering microbiome composition to influence metabolic pathways, potentially reducing ammonia production or enhancing its clearance. Development reached **Phase 2** trials in the United Kingdom (started 17 Sep 2019) and Switzerland (started 31 Dec 2018), but the program appears **discontinued**, with no evidence of further advancement or approval.[3][7][9]

Other names: gluco-oligosaccharide mixture

Beyond the preview

Go deeper on onterodrimer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on onterodrimer.

Explore the full profile